Ignyta has formed a license agreement with Nerviano Medical Sciences that grants Ignyta exclusive global development and marketing rights to RXDX-101, a tyrosine kinase inhibitor directed to the TrkA, ROS1 and ALK proteins; and RXDX-102, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors. Nerviano is a former Pfizer/Pharmacia oncology discovery site in Italy.

RXDX-101 is in a phase I/II clinical study in molecularly defined patient populations for the treatment of solid tumors. RXDX-102 currently is in preclinical development for the treatment of multiple cancers.

The license agreement will become effective upon Ignyta’s completion of an equity or debt financing resulting in proceeds of at least $20 million. Ignyta will assume sole responsibility for global development and commercialization of RXDX-101 and RXDX-102. Nerviano will be entitled to receive certain upfront and milestone payments, as well as tiered royalty payments on future net sales.